太極集團(600129.SH)及子公司擬8.38億元合計轉讓成都新衡生公司95%股權
格隆匯9月28日丨太極集團(600129.SH)公佈,公司擬轉讓持有控股股子公司成都新衡生房地產開發有限公司(成都新衡生公司)59.42%的股權給重慶太衡企業管理諮詢有限公司(太衡公司),轉讓總金額為約5.24億元;公司全資子公司太極集團重慶涪陵製藥廠有限公司(涪陵製藥廠)擬轉讓持有成都新衡生公司35.58%的股權給太衡公司,轉讓總金額為約3.14億元。上述轉讓金額合計為約8.38億元。轉讓後,公司持有成都新衡生公司5%的股權,不再對成都新衡生公司控股。
此次股權轉讓,有利於公司專注醫藥大健康產業發展,做大做強醫藥產業,同時盤活閒置資產,提高資產使用價值,增加公司流動資金和拓寬利潤來源。
經公司財務部門初步測算,此次股權轉讓,公司將獲得收益約3.89億元,預計對公司本年度經營收益帶來積極影響,具體金額以公司經審計確認的數據為準。敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.